Experience in the use of Brirosa and Rozacom in secondary glaucoma

Authors

  • N.V. Konovalova The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa, Ukraine, Ukraine
  • N.I. Khramenko The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa, Ukraine, Ukraine
  • O.V. Guzun The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa, Ukraine, Ukraine
  • A.V. Kovtun Odessa National Medical University, Odesa, Ukraine, Ukraine

DOI:

https://doi.org/10.22141/2309-8147.9.2.2021.241504

Keywords:

secondary glaucoma, Briroza, Rozacom

Abstract

Background. Glaucoma is one of the most acute medical and social problems that cause enormous economic damage to society. Secondary glaucoma is the result of complications of such eye diseases as inflammation of the choroid of the eye, retinal vascular thrombosis. The purpose was to determine the effect of Briroza and Rozacom on the condition of the visual analyzer in patients with secondary glaucoma. Material and methods. The study involved 58 patients (58 eyes) with a unilateral process. All patients were divided into three groups. Groups 1 and 2 consisted of the patients with se-
condary glaucoma after anterior recurrent iridocyclitis — 32 patients (32 eyes) in remission and relapse, respectively. Group 3 included patients with secondary (neovascular) glaucoma, which resulted from the central vein stenosis (CVS) and its branches — 26 patients (26 eyes). Results. In the first and second groups, Briroza administration resulted in the intraocular pressure decrease by 21.6 % (p = 0.001) — 21.0 ± 3.5 mm Hg. After a course of treatment in groups 1 and 2, electrical phosphene excitation decreased significantly by 22.4 % (p < 0.05). The critical frequency of flicker-induced phosphene in the mode 3 and 1.5 increased by 20.6 % (p < 0.05) and 47 % (p < 0.05), which indicates an increase in the functional activity of visual analyzer. Conclusions. The inclusion of the drugs Briroza and Rozacom twice a day for 2 months in the treatment of patients with secondary glaucoma is effective due to the increased functional activity of the visual analyzer and normalization of intraocular pressure in patients with secondary glaucoma.

References

Moiseenko R.O., Golubchikov M.V., Rykov S.O. (Ed.). Ophthalmological care in Ukraine during the years of Independence: Analytically stat. directory. Kropyvnytskyi: Podium, 2019.

Bikbov M.M., Babushkin A.E., Orenburkina O.I. Results of surgical treatment of neovascular glaucoma using VEGF blockers. Clinical ophthalmology. 2011. № 1. 21 p.

European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th еdition. Part 1. Supported bythe EGS Foundation. Br. J. Ophthalmol. 2017. 101(4). 1-72.

Quigley H.A., Broman A.T. The number of people with glaucoma world wide in 2010 and 2020. Br. J. Ophthalmol. 2006. 90(3). 262-267.

Hurtado O., Moro M.A., Cardenas A. et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol. Dis. 2005. 18. 336-345.

Zueva M.V. Dynamics of retinal ganglion cell death in glaucoma and its functional markers. National Glaucoma Journal. 2014. 2016. 15 (1). 70-85.

Kurysheva N.I., Azizova O.A., Piryazev A.P. Antioxidant activity of a fixed combination of dorzolamide with timolol in terms of neuroprotection in glaucoma. Ophthalmology. 2012. 9 (4). 47-51. https://doi.org/10.18008/1816-5095-2012-4-47-51.

Sena D.F., Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev. 2017. 1. CD006539. https://doi.org/10.1002/14651858.CD006539.pub4.

Brown D.M. Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study. Ophthalmology. 2014 Jan. 121. Is. 1. 209-219.

Nucci C., Martucci A., Giannini C., Morrone L.A., Ba­getta G., Mancino R. Neuroprotective agentsin the management of glaucoma. Eye (Lond.). 2018. 32(5). 938-45.

Marchenko L.N. Neuroprotection in diseases of the retina and optic nerve. Minsk: UP IBC Minfsn, 2003. 363 p.

Guzun O.V., Khramenko N.I., Chechin P.P., Zadorozhnyy O.S., Nasinnyk I.O., Korol A.R. Changes of Intraocular Pressure and Ocular Hemodinamics in Patients with Neovascular Glaucoma after Transscleral Laser Cyclocoagulation. 2019 IEEE 8th International Conference on Advanced Optoelectronics and Lasers (CAOL), Sozopol, Bulgaria, 06-08 September, 2019. 122-125.

Пономарчук В.С. Фосфенэлектродиагностика в офтальмологии. Одесса: Астропринт, 2018. 104 с.

Чечин П.П., Гузун О.В., Храменко Н.И., Перетягин О.А. Эффективность неодимовой транссклеральной лазерциклокоагуляции и изменение кровообращения глаза у больных с абсолютной глаукомой. Офтальмол. журн. 2018. № 2. С. 34-40.

Published

2021-10-19

Issue

Section

Exchange of Experience